BioHarvest Sciences (BHST) H.C. Wainwright 28th Annual Global Investment Conference summary

Strategic vision and leadership

• CEO emphasized personal investment of $18 million and conviction in the company's future.

• Leadership team includes veterans from biotech, data science, consumer goods, and finance.

• Focus on building a unique platform for plant-based molecule production.

• Company operates R&D and manufacturing in Israel.

Technology and innovation

• Developed proprietary Botanical Synthesis process using programmable biology and AI.

• Industrialized cell culture to produce plant molecules at scale in bioreactors.

• Technology enables consistent, scalable, and patentable production of plant-derived molecules.

• AI optimizes molecule production and reduces development time and contamination risk.

Product portfolio and applications

• Commercialized VINIA, a red grape cell-based product, with over $100 million in cumulative sales.

• Pipeline includes molecules from olive, pomegranate, saffron, and fragrance trees.

• Applications span nutraceuticals, pharmaceuticals, cosmeceuticals, nutrition, and fragrances.

• Announced major fragrance supply agreement worth $20–$30 million over the next few years.